home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Genetic News | search  
 

Regulation Of Nitric Oxide Activity For Disease Treatment

 
  August, 1 2001 23:58
your information resource in human molecular genetics
 
     
Indirectly regulating nitric oxide activity

Nitric oxide (NO) has been shown to have a role in a number of conditions, including diabetes, hypertension, cancer, and impotence. This signaling molecule is present at low levels in all parts of the body and is involved in many important functions, including control of blood flow, neurotransmission, and protection from bacterial infection. In pathological condition such as inflammation, however, NO levels increase and become detrimental.

One potential way to decrease NO levels for disease treatment is to inhibit the enzyme NO synthase, which is responsible for creating it. This enzyme uses the amino acid arginine to release NO, so potential inhibitors include molecules that look like arginine and are recognized and bound by the enzyme, but cannot be used to create NO. Efforts are currently being directed toward developing such inhibitors, but it turns out there are naturally-occurring compounds that do this job. The levels of these inhibitory compounds are regulated primarily by another enzyme, 'dimethylarginine dimethylaminohydrolase' (DDAH), which works to eliminate them. Inhibiting DDAH, therefore, would lead to increased levels of natural NO synthase inhibitors, which may represent a new tactic for treating diseases related to increased NO levels.

In the August issue of Nature Structural Biology (Vol. 8, No. 8, 01 Aug 2001, pages 679-683), Neil McDonald at the Imperial Cancer Research Fund in London and colleagues report the structure of the enzyme DDAH. They find that it looks similar to other enzymes that work on derivatives of arginine, and propose a reaction mechanism for how it works to eliminate the arginine-related NO synthase inhibitors. This structure provides a basis for designing inhibitors for this enzyme, potentially providing a new way of indirectly regulating NO activity.

Contact:

Dr. Neil Q. McDonald
Imperial Cancer Research Fund
Structural Biology Laboratory
44 Lincoln's Inn Fields
Rm315
Holborn
London, WC2A3PX
UK
Telephone #: +44 20 269 3259
Fax #: +44 20 269 3258
Email Address: n.mcdonald@icrf.icnet.uk

Nature Structural Biology press release.


Message posted by: Trevor M. D'Souza

print this article mail this article
Bookmark and Share this page (what is this?)

Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.

Use the links below to share this article on the social bookmarking site of your choice.

Read more about social bookmarking at Wikipedia - Social Bookmarking

Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2016 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.